Update cookies preferences

Free Download

EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023

Volume: 61 - Issue: 3

First page: 194 - Last page: 202

W.J. Fokkens - A-S. Viskens - V. Backer - D. Conti - E. De Corso - P. Gevaert - G.K. Scadding - M. Wagemann - M. Bernal-Sprekelsen - A. Chaker - E. Heffler - J.K. Han - E. Van Staeyen - C. Hopkins - J. Mullol - A. Peters - S. Reitsma - B.A. Senior - P.W. Hellings

DOI: 10.4193/Rhin22.489

Severe chronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating disease with a significant impact on the quality of life (QoL). It is typically characterized by a type 2 inflammatory reaction and by comorbidities such as asthma, allergies and NSAID-Exacerbated Respiratory Disease (N-ERD). Here, the European Forum for Research and Education in Allergy and Airway diseases discusses practical guidelines for patients on biologic treatment. Criteria for the selection of patients who would benefit from biologics were updated. Guidelines are proposed concerning the monitoring of the drug effects that provide recognition of responders to the therapy and, subsequently, the decision about continuation, switching or discontinuation of a biologic. Furthermore, gaps in the current knowledge and unmet needs were discussed.

Rhinology 61-3: 194-202, 2023

To see the issue content and the abstract you do not have to login

Please login to download the full articles

If you do not have a subscription to Rhinology please consider taking one.

Click here to become a member of the European Rhinologic Society and a subscriber to the journal `RHINOLOGY`, from 2024. Subscription including membership fee: Euro 135.-